Market News & Trends
DFE Pharma Demonstrates Impact of Powder Properties on the Rheological Behavior of Excipients
DFE Pharma, a global leader in pharmaceutical excipient solutions, is continuously supporting relevant scientific research and innovations in its field. With the recent publication of…
TriRx Hosted State & Community Leaders to Celebrate Acquisition of Shawnee, KS, Facility
TriRx Pharmaceutical Services, LLC, a leading international CDMO, hosted Kansas Lt. Governor David Toland, Shawnee Mayor Michelle Distler, State Senator Mike Thompson, Congresswoman Jo Ella…
Q BioMed Signs Distribution Agreement With isoSolutions for the Sales of Strontium89 in Canada
Q BioMed Inc. recently announced it has entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing…
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of COVID-19 Infection & Associated Coagulopathy With rNAPc2
ARCA biopharma, Inc. recently announced it has submitted a Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications, for the use…
Catalent to Supply Edenbridge Pharmaceuticals With a Fast-Dissolve Zydis Formulation of Glycopyrrolate Intended as Adjunctive Therapy for Patients With Peptic Ulcer
Catalent recently announced it has signed a commercial supply agreement with Edenbridge Pharmaceuticals, LLC, for a novel formulation of glycopyrrolate using Catalent’s proprietary Zydis orally…
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
Aravive Inc. recently announced it has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with…
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Study of FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. recently announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy…
Sensirion Expands its Flow Sensor Portfolio for Ventilators
Sensirion, the sensor expert for medical ventilation and the world’s leading manufacturer of flow sensors, is expanding its product portfolio for the MD&M West 2021…
Apollomics Doses First Patient in a Phase 1 Clinical Trial of APL-102
Apollomics Inc. recently announced the successful dosing of the first patient in a Phase 1 clinical study of APL-102 in patients with advanced solid tumors.…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….